CVAC Overview

CureVac CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).

Wall Street analysts forecast CVAC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CVAC is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

CureVac NV revenue for the last quarter amounts to 54.13M USD, decreased -89.04

CureVac NV. EPS for the last quarter amounts to 1.21 USD, decreased -19.33

CureVac NV (CVAC) has 825 emplpoyees as of April 01 2026.

Today CVAC has the market capitalization of 753.67M USD.